Novo Holdings invests in macrocycle startup Orbis as once-overlooked molecules get new interest
29 Feb 2024
At long last, macrocycles are spinning into the spotlight.
On Thursday, Orbis Medicines launched with €26 million in seed funding from European VC fund Forbion and Novo Holdings, the investment arm of Novo Nordisk’s parent foundation. The startup is focused on developing peptide drugs based on macrocycles, which are small chemical rings.
Most macrocycle drugs, such as cyclosporine or a component of Neosporin, have been discovered in nature, but the molecules were for a long time left on the sidelines by drug developers because they had difficulty passing through membranes, an important quality for many pill-based medicines. However, recent advances in designing peptides have shown it’s possible to overcome that obstacle and have rekindled interest in the potential for macrocyclic medicines.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.